공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

외음부암 : 파이프라인 리뷰

Vulvar Cancer - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 361638
페이지 정보 영문 243 Pages
가격
US $ 2,000 ₩ 2,291,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,582,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,873,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


외음부암 : 파이프라인 리뷰 Vulvar Cancer - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 243 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

외음부암(Vulvar Cancer) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 및 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스 및 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

외음부암 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

외음부암 : 기업에서 개발중인 치료제

외음부암 : 대학/기관에서 연구중인 치료제

외음부암 : 파이프라인 제품 개요

  • 임상 단계 제품

외음부암 : 기업에서 개발중인 제품

외음부암 : 대학/기관에서 연구중인 제품

외음부암 치료제 개발에 참여하고 있는 기업

  • ISA Pharmaceuticals B.V.
  • Ono Pharmaceutical Co., Ltd.
  • Oryx GmbH & Co. KG
  • PDS Biotechnology Corporation

외음부암 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

외음부암 : 최근의 파이프라인 동향

외음부암 : 휴지중인 프로젝트

외음부암 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.01

List of Tables

  • Number of Products under Development for Vulvar Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Vulvar Cancer - Pipeline by Antiva Biosciences Inc, H2 2019
  • Vulvar Cancer - Pipeline by AstraZeneca Plc, H2 2019
  • Vulvar Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Vulvar Cancer - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
  • Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2019
  • Vulvar Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Vulvar Cancer - Pipeline by Gilead Sciences Inc, H2 2019
  • Vulvar Cancer - Pipeline by Invectys SA, H2 2019
  • Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2019
  • Vulvar Cancer - Pipeline by Merck & Co Inc, H2 2019
  • Vulvar Cancer - Pipeline by Merck KGaA, H2 2019
  • Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Vulvar Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
  • Vulvar Cancer - Pipeline by SQZ Biotechnologies Co, H2 2019
  • Vulvar Cancer - Pipeline by Transgene SA, H2 2019
  • Vulvar Cancer - Pipeline by Turnstone Biologics Inc, H2 2019
  • Vulvar Cancer - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Vulvar Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2019, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 13, 4 and 2 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vulvar Cancer - Overview
    • Vulvar Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Vulvar Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Vulvar Cancer - Companies Involved in Therapeutics Development
    • Antiva Biosciences Inc
    • AstraZeneca Plc
    • Bristol-Myers Squibb Co
    • Brooklyn ImmunoTherapeutics LLC
    • Cutanea Life Sciences Inc
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc
    • Invectys SA
    • ISA Pharmaceuticals BV
    • Merck & Co Inc
    • Merck KGaA
    • Ono Pharmaceutical Co Ltd
    • Shanghai Bovax Biotechnology Co Ltd
    • SQZ Biotechnologies Co
    • Transgene SA
    • Turnstone Biologics Inc
  • Vulvar Cancer - Drug Profiles
  • Vulvar Cancer - Dormant Projects
  • Vulvar Cancer - Discontinued Products
  • Vulvar Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q